Prophylaxis against respiratory syncytial virus with monoclonal antibodies (palivizumab). An overview through evidence based medicine;La profilaxis frente al virus respiratorio sincitial con anticuerpos monoclonales (palivizumab). Una panorámica a través de la medicina basada en la evidencia

Revista Espanola de Pediatria

Volumn 59, Issue 5, 2003, Pages 391-402

  González de Dios, Javier ^a,c   Ochoa Sangrador, C ^b  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB; PLACEBO;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; HUMAN; INFANT; INFANT MORTALITY; INFECTION CONTROL; MAJOR CLINICAL STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; OXYGEN THERAPY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0242267438     PISSN: 0034947X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Martinón Torres F, Rodríguez Núñez A, Martinón Sánchez JM. Bronquiolitis aguda: evaluación del tratamiento basado en la evidencia. An Esp Pediatr 2001; 55: 345-54.
2. González Caballero D, González Pérez-Yarza E. Bronquiolitis aguda: bases para un protocolo racional. An Esp Pediatr 2001; 55: 355-64.
3. Bonillo Perales A. Bronquiolitis: necesidad de consenso asistencial. An Esp Pediatr 2001; 55: 297-9.
4. Puigventós Latorre F. Novedades terapéuticas del año 2000: los retos del médico y del gestor. Med Clin (Barc) 2001; 116: 465-8.
5. Danés Carreras I, Arnaua de Bolós JM. Profilaxis de las infecciones por el virus respiratorio sincitial con palivizumab. An Esp Pediatr 2002; 56: 289-91.
6. González de Dios J. De la medicina basada en la evidencia a la evidencia basada en la medicina. An Esp Pediatr 2001; 55: 429-39.
7. Evidence-Based Medicine Working Group. Evidence-Based Medicine. A new approach to teaching the practice of medicine. JAMA 1992; 268: 2420-5.
8. Oxman AD, Sackett DL, Guyatt GH, for the Evidence-Based Medicine Working Group. User's guide to the medical literature. I. How to get started. JAMA 1993; 270: 2093-5.
9. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drugs events in infants and children under 2 years of age [en línea] [fecha de consulta: 5-XII-2002]. Pediatrics electronic 2002; vol 110. URL disponible en: http://www.pediatrics.org/cgi/content/full/110/5/e53.
10. Meissner HC. Uncertainty in the management of viral lower respiratory tract disease. Pediatrics 2001; 108: 1000-3.
11. Buñuel Alvarez JC. Medicina basada en la evidencia: una nueva manera de ejercer la pediatría. An Esp Pediatr 2001; 55: 440-52.
12. Wang EEL, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review). En: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.
13. Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost effectiveness analysis. Clin Ther 2000; 22: 1357-69.
14. Atkins JT, Karimi P, Morris BH, McDavid G, Shim S. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immune globulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr Infect Dis J 2000; 19: 138-43.
15. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decisions and costs. Pediatr Pulmonol 2001; 32: 20-8.
16. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154: 55-61.
17. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants. A systematic review. Arch Pediatr Adolesc Med 2002; 156: 1034-41.
18. Evidence based clinical practice guidelines for the infant with bronchiolitis. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2001 [en línea] [fecha de consulta: 5-XII-2002]. URL disponible en: http://www.guidelines.gov/FRAMESETS/guideline_fs.asp?view=full_summary & guideline=002339&sSearch.string=bronchiolitis
19. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. IMpact-RSV Study Group. Pediatrics 1998; 102: 531-7.
20. Sorrentino M, Powers T and The Palivizumab Outcomes Study Group. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J. 2000; 19: 1068-71.
21. Vogel A, Lennon D, Broadbent R, Byrnes C, Grimwood K, Mildenhall L, et al. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health. 2002; 38: 550-4.
22. Lacaze-Masmonteil T, Roze JC, Fauroux B, French Pediatricians' Group of Synagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Pediatr Pulmonol 2002; 34: 181-8.
23. Oh PI, Lanctjt KL, Yoon A, Lee DS, Paes BA, Simmons BS, et al. The Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002; 21: 512-8.
24. Lapeña López de Armentia S, Castañón López L, Martínez Badás JP, Álvaro Iglesias E. Hospitalización por bronquiolitis aguda, edad de gestación y palivizumab. An Esp Pediatr 2001; 55: 378.
25. Grupo de Hospitales Benazuza. Quimioprofilaxis con palivizumab en Andalucía. Resultados de la epidemia de VRS 2000-2001. An Esp Pediatr 2002; 56: 293-7.
26. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998; 102: 1211-6.
27. Carbonell Estrany X, Quero Jiménez J y Comité de Estándares de la Sociedad Española de Neonatología y Junta Directiva de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Esp Pediatr 2000; 52: 372-4.
28. Carbonell Estrany X, Quero Jiménez J y Comité de Estándares de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Esp Pediatr 2002; 56: 334-6.
29. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419-27.
30. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther. 1999; 21: 752-66.
31. Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics 2000; 106: 520-6.
32. Thomas M, Bedford-Rusell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000; 83: 122-7.
33. Numa A. Outcome of respiratory syncitial virus infection and a cost-benefit analysis of prophylaxis. J Pediatr Child Health 2000; 36: 422-27.
34. Shireman TI, Braman KS. Impact and Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis for Kansas Medicaid's High-Risk Children. Arch Pediatr Adolesc Med 2002; 156: 1251-5.
35. Birken CS, Parkin PC. In wich journals will pediatricians find the best evidence for clinical practice? Pediatrics 1999; 103: 941-7.
36. González de Dios J. Información y publicaciones en biomedicina: Pasado, presente y futuro. An Esp Pediatr 2002; 56 (supl 6): 255-9.
37. Aguillo IE Herramientas avanzadas para la búsqueda de información médica en el web. Aten Primaria 2002; 29: 246-53.
38. Bravo Acuña J, Merino Moína M. Pediatría e Internet. Aten Primaria 2001; 27: 574-8.
39. Carbonell-Estrany X, Quero J and IRIS Study Group. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000; 19: 592-7.
40. Carbonell-Estrany X, Quero J, and IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001; 20: 874-9.
41. Bonillo Perales A, Díez-Delgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria MR, Batllés Garrido J, et al. Antecedentes perinatales y hospitalización por bronquiolitis. Comparación con el Impact-RSV Study Group. An Esp Pediatr 2000; 53: 527-32.
42. Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics 1999; 104: 559-60.
43. Guyatt GH, Sackett FL, Cook DJ. User's guides to the medical literature. II. How to use an article about therapy or prevention: A. Are the results of the study valid? JAMA 1993; 270: 2598-601.
44. Guyatt GH, Sackett FL, Cook DJ. User's guides to the medical literature. II. How to use an article about therapy or prevention: B. What are the results and will they help me in caring for my patients? JAMA 1994; 271: 59-63.
45. Connor EM, Carlin D, Top FH, Weishman LE. Who shall not receive palivizumab? Pediatrics 2000; 106: 866-7.
46. Drummond MF, Richardson WS, O'Brien B, Levine M, Heyland D. User's guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice: A. Are the results of the study valid? JAMA 1997; 277: 1552-7.
47. O'Brien BJ, Heyland D, Richardson WS, Levine M, Drummond ME User's guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice: B. What are the results and will they help me in caring for my patients? JAMA 1997; 277: 1802-6.
48. Groothuis JR, Simoes EA, Hemming VG. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 1995; 95: 463-7.
49. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93-9.
50. Joffe S, Escobar GJ, Armstrong MA, Black SB, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999; 104: 894-9.
51. Kranczer S. Mixed life expectancy changes. Stat Bull 1996; 77: 29-36.
52. Simoes EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002; 3 (supl 1): S26-S33.
53. Davidoff F, DeAngelis CD, Drazen JM, Nichols MG, Hoey J, Hojgaard L, et al. Sponsorship, authorship, and accountability. N Engl J Med 2001; 345: 825-7.
54. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-7.
55. Soto J, Olivella P. ¿Son los medicamentos una inversión económicamente rentable para el sistema nacional de salud en España? Med Clin (Barc) 2001; 117: 622-4.